1 Min Read
Nov 16 (Reuters) - Novartis AG:
* FDA APPROVES NOVARTIS DRUG PROMACTA® FOR FIRST-LINE SAA AND GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR ADDITIONAL NEW INDICATION Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.